STOCK TITAN

AXIM Biotechnologies, Inc. - AXIM STOCK NEWS

Welcome to our dedicated page for AXIM Biotechnologies news (Ticker: AXIM), a resource for investors and traders seeking the latest updates and insights on AXIM Biotechnologies stock.

AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on revolutionizing the diagnosis and treatment of oncology and SARS-CoV-2 (COVID-19). The company's flagship product, Neucovix, is a rapid diagnostic test that measures functional neutralizing antibodies to prevent SARS-CoV-2 infection. Additionally, AXIM Biotechnologies is developing rapid diagnostic tests for early cancer detection and proprietary small molecule drugs to treat cancer and inhibit metastasis. Founded in 2010, the company is headquartered in San Diego, California.

Rhea-AI Summary
AXIM Biotechnologies, Inc. CEO John Huemoeller II discusses the company's FDA-cleared diagnostic assays for dry eye disease and allergies in a fireside chat interview. The company is focused on providing quantitative diagnostic solutions using teardrops, with tests for Lactoferrin and IgE. The interview sheds light on AXIM's research in Parkinson's diagnostic program and its impact on treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
Rhea-AI Summary
AXIM Biotechnologies' commercialization partner, Verséa Ophthalmic, places a re-stock order for AXIM's digital assay reader, indicating a growing clinical presence and revenue opportunity. The order reflects successful clinical validation and an impending expansion of AXIM's diagnostic program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
none
-
Rhea-AI Summary
AXIM Biotechnologies, Inc. (OTCQB: AXIM) has signed a contract manufacturing agreement with Auer Precision to scale production of its FDA-cleared diagnostic assays for Dry Eye Disease. The partnership aims to meet the growing demand for the tests in a cost-effective way, enabling AXIM to focus on research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
AXIM develops rapid diagnostic assay for Parkinson's Disease biomarker
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
AXIM Biotechnologies, Inc. (OTCQB: AXIM) announces the expansion of its IP portfolio with 13 filings and allowances, covering a wide range of diagnostic solutions including SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9, and cancer biomarkers. The USPTO has granted patents for COVID-19 neutralizing antibody testing, rapid diagnostics for cancers, and point-of-care cancer detection methods, enhancing the company's value proposition and market potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none

FAQ

What is the focus of AXIM Biotechnologies, Inc.?

AXIM Biotechnologies focuses on changing the landscape of oncology and SARS-CoV-2 diagnosis and treatment.

What is Neucovix?

Neucovix is a rapid diagnostic test developed by AXIM Biotechnologies to measure functional neutralizing antibodies against SARS-CoV-2.

What other products is AXIM Biotechnologies working on?

The company is developing rapid diagnostic tests for early cancer detection and proprietary small molecule drugs for cancer treatment and metastasis prevention.

When was AXIM Biotechnologies founded?

The company was founded in 2010.

Where is AXIM Biotechnologies headquartered?

AXIM Biotechnologies is headquartered in San Diego, California.

What was the previous name of AXIM Biotechnologies?

The company was formerly known as AXIM International Inc. before changing its name in July 2014.

What is the primary goal of AXIM Biotechnologies?

AXIM Biotechnologies aims to provide innovative diagnostic solutions for ophthalmological conditions like Dry Eye Disease.

What is the significance of the contract manufacturing agreement with Auer Precision?

The agreement will enable AXIM Biotechnologies to scale up the production of its FDA-cleared diagnostic assays for Dry Eye Disease in a cost-effective manner.

Who is AXIM Biotechnologies' commercialization partner?

Verséa Ophthalmics is AXIM Biotechnologies' commercialization partner involved in marketing its proprietary ocular diagnostic assays.

How are AXIM's ocular diagnostic assays improving healthcare?

The tests provide clinicians with quantitative measurements to diagnose and treat conditions like Dry Eye Disease at the point-of-care, addressing a critical unmet need in ophthalmological healthcare.

AXIM Biotechnologies, Inc.

OTC:AXIM

AXIM Rankings

AXIM Stock Data

3.18M
217.66M
25.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
San Diego